[Form 4] ALX Oncology Holdings Inc. Insider Trading Activity
ALX Oncology Holdings Inc. (ALXO) Chief Financial Officer Shantharam Harish reported a purchase of 75,000 shares of the company on 08/18/2025. The reported price is a weighted average of $0.7787 per share, with individual trade prices ranging from $0.6823 to $0.9234; the filer agrees to provide a breakdown of quantities at each price upon request. Following the transaction the reporting person beneficially owns 75,000 shares directly. The Form 4 was signed by an authorized representative on 08/20/2025.
ALX Oncology Holdings Inc. (ALXO) Il Chief Financial Officer Shantharam Harish ha comunicato l'acquisto di 75.000 azioni della societ脿 in data 18/08/2025. Il prezzo riportato 猫 una media ponderata di $0,7787 per azione, con singole operazioni comprese tra $0,6823 e $0,9234; il dichiarante si rende disponibile a fornire, su richiesta, la ripartizione delle quantit脿 per ciascun prezzo. Dopo l'operazione, la persona segnalante detiene direttamente 75.000 azioni. Il Modulo 4 猫 stato firmato da un rappresentante autorizzato il 20/08/2025.
ALX Oncology Holdings Inc. (ALXO) El Director Financiero Shantharam Harish inform贸 la compra de 75.000 acciones de la compa帽铆a el 18/08/2025. El precio declarado es un promedio ponderado de $0,7787 por acci贸n, con operaciones individuales entre $0,6823 y $0,9234; el declarante acepta proporcionar, a petici贸n, el desglose de cantidades por cada precio. Tras la transacci贸n, la persona que informa posee directamente 75.000 acciones. El Formulario 4 fue firmado por un representante autorizado el 20/08/2025.
ALX Oncology Holdings Inc. (ALXO) 斓滉碃鞛毂呾瀯鞛�(Chief Financial Officer) Shantharam Harish臧� 2025雲� 08鞗� 18鞚� 須岇偓 欤检嫕 75,000欤茧ゼ 毵れ垬頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 氤搓碃霅� 臧�瓴╈潃 欤茧嫻 臧�欷戫弶攴� $0.7787鞚措┌, 臧滊硠 瓯半灅 臧�瓴╈潃 $0.6823鞐愳劀 $0.9234 靷澊鞛呺媹雼�. 鞝滌稖鞛愲姅 鞖旍箔 鞁� 臧� 臧�瓴╇寑氤� 靾橂焿 雮挫棴鞚� 鞝滉车頃橁矤雼り碃 頄堨姷雼堧嫟. 瓯半灅 頉� 氤搓碃鞛愲姅 歆侅爲 75,000欤茧ゼ 氤挫湢頃橁矊 霅╇媹雼�. Form 4電� 甓岉暅 鞛堧姅 雽�毽澑鞚� 2025雲� 08鞗� 20鞚检棎 靹滊獏頄堨姷雼堧嫟.
ALX Oncology Holdings Inc. (ALXO) Le directeur financier Shantharam Harish a d茅clar茅 l'achat de 75 000 actions de la soci茅t茅 le 18/08/2025. Le prix d茅clar茅 est une moyenne pond茅r茅e de 0,7787 $ par action, les transactions individuelles variant de 0,6823 $ 脿 0,9234 $ ; le d茅clarant accepte de fournir, sur demande, le d茅tail des quantit茅s 脿 chaque prix. 脌 la suite de la transaction, la personne d茅clarant poss猫de directement 75 000 actions. Le formulaire 4 a 茅t茅 sign茅 par un repr茅sentant autoris茅 le 20/08/2025.
ALX Oncology Holdings Inc. (ALXO) Chief Financial Officer Shantharam Harish meldete am 18.08.2025 den Kauf von 75.000 Aktien des Unternehmens. Der gemeldete Preis ist ein gewichteter Durchschnitt von $0,7787 pro Aktie, einzelne Transaktionen lagen zwischen $0,6823 und $0,9234; der Meldende erkl盲rt sich bereit, auf Anfrage eine Aufschl眉sselung der St眉ckzahlen zu den jeweiligen Preisen vorzulegen. Nach der Transaktion besitzt die meldende Person direkt 75.000 Aktien. Das Formular 4 wurde am 20.08.2025 von einem bevollm盲chtigten Vertreter unterschrieben.
- None.
- None.
Insights
TL;DR: CFO purchased 75,000 shares at a weighted average $0.7787, signalling insider buying but magnitude relative to holdings is unspecified.
The direct acquisition of 75,000 common shares by the Chief Financial Officer on 08/18/2025 is a clear insider purchase disclosed on Form 4. The filing reports a weighted average price of $0.7787 with trades between $0.6823 and $0.9234; the filer offers to disclose per-trade quantities if requested. Insider purchases can be interpreted as a confidence signal, though the materiality of this transaction versus total outstanding shares or the CFO's total holdings is not provided in the filing, limiting valuation impact analysis.
TL;DR: Procedurally compliant Form 4 filing shows an officer purchase; disclosure includes required price-range explanation.
The Form 4 properly identifies the reporting person, relationship to the issuer (Chief Financial Officer), transaction date, transaction code (P), and the weighted average price with an explanatory footnote. The signature by power of attorney is present. No amendments or additional derivative positions are reported. From a governance and compliance perspective, the filing appears complete and timely based on the included data.
ALX Oncology Holdings Inc. (ALXO) Il Chief Financial Officer Shantharam Harish ha comunicato l'acquisto di 75.000 azioni della societ脿 in data 18/08/2025. Il prezzo riportato 猫 una media ponderata di $0,7787 per azione, con singole operazioni comprese tra $0,6823 e $0,9234; il dichiarante si rende disponibile a fornire, su richiesta, la ripartizione delle quantit脿 per ciascun prezzo. Dopo l'operazione, la persona segnalante detiene direttamente 75.000 azioni. Il Modulo 4 猫 stato firmato da un rappresentante autorizzato il 20/08/2025.
ALX Oncology Holdings Inc. (ALXO) El Director Financiero Shantharam Harish inform贸 la compra de 75.000 acciones de la compa帽铆a el 18/08/2025. El precio declarado es un promedio ponderado de $0,7787 por acci贸n, con operaciones individuales entre $0,6823 y $0,9234; el declarante acepta proporcionar, a petici贸n, el desglose de cantidades por cada precio. Tras la transacci贸n, la persona que informa posee directamente 75.000 acciones. El Formulario 4 fue firmado por un representante autorizado el 20/08/2025.
ALX Oncology Holdings Inc. (ALXO) 斓滉碃鞛毂呾瀯鞛�(Chief Financial Officer) Shantharam Harish臧� 2025雲� 08鞗� 18鞚� 須岇偓 欤检嫕 75,000欤茧ゼ 毵れ垬頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 氤搓碃霅� 臧�瓴╈潃 欤茧嫻 臧�欷戫弶攴� $0.7787鞚措┌, 臧滊硠 瓯半灅 臧�瓴╈潃 $0.6823鞐愳劀 $0.9234 靷澊鞛呺媹雼�. 鞝滌稖鞛愲姅 鞖旍箔 鞁� 臧� 臧�瓴╇寑氤� 靾橂焿 雮挫棴鞚� 鞝滉车頃橁矤雼り碃 頄堨姷雼堧嫟. 瓯半灅 頉� 氤搓碃鞛愲姅 歆侅爲 75,000欤茧ゼ 氤挫湢頃橁矊 霅╇媹雼�. Form 4電� 甓岉暅 鞛堧姅 雽�毽澑鞚� 2025雲� 08鞗� 20鞚检棎 靹滊獏頄堨姷雼堧嫟.
ALX Oncology Holdings Inc. (ALXO) Le directeur financier Shantharam Harish a d茅clar茅 l'achat de 75 000 actions de la soci茅t茅 le 18/08/2025. Le prix d茅clar茅 est une moyenne pond茅r茅e de 0,7787 $ par action, les transactions individuelles variant de 0,6823 $ 脿 0,9234 $ ; le d茅clarant accepte de fournir, sur demande, le d茅tail des quantit茅s 脿 chaque prix. 脌 la suite de la transaction, la personne d茅clarant poss猫de directement 75 000 actions. Le formulaire 4 a 茅t茅 sign茅 par un repr茅sentant autoris茅 le 20/08/2025.
ALX Oncology Holdings Inc. (ALXO) Chief Financial Officer Shantharam Harish meldete am 18.08.2025 den Kauf von 75.000 Aktien des Unternehmens. Der gemeldete Preis ist ein gewichteter Durchschnitt von $0,7787 pro Aktie, einzelne Transaktionen lagen zwischen $0,6823 und $0,9234; der Meldende erkl盲rt sich bereit, auf Anfrage eine Aufschl眉sselung der St眉ckzahlen zu den jeweiligen Preisen vorzulegen. Nach der Transaktion besitzt die meldende Person direkt 75.000 Aktien. Das Formular 4 wurde am 20.08.2025 von einem bevollm盲chtigten Vertreter unterschrieben.
